/
ICCM
$5.26-$0.70 (-11.74%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$20.4M
3M shares
52-week range
$2.12 – $42.00
8% from low
Exchange
NASDAQ
CS
Borrow rate
546.13%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-321.74
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $4.1M | $4.1M | $3.1M | $3.2M | $3.3M | $3.4M |
| Cost of revenue | $623.2K | $1.1M | $1.4M | $1.9M | $1.6M | $1.9M | $1.8M | $2.2M |
| Gross profit | $448.7K | $576.4K | $2.7M | $2.2M | $1.4M | $1.3M | $1.5M | $1.2M |
| Gross margin | 41.9% | 34.8% | 65.1% | 53.0% | 46.8% | 40.3% | 44.1% | 36.3% |
| R&D | $1.9M | $2.8M | $4.1M | $5.9M | $9.1M | $8.3M | $7.1M | $7.4M |
| Operating income | −$3.2M | −$4.6M | −$4.4M | −$9.7M | −$16.7M | −$15.6M | −$15.7M | −$15.1M |
| EBITDA | −$3.4M | −$4.6M | −$4.1M | −$9.6M | −$16.5M | −$15.3M | −$15.4M | −$14.8M |
| Net income | −$3.5M | −$4.8M | −$4.8M | −$10.1M | −$17.2M | −$14.7M | −$15.3M | −$15.1M |
| Net margin | -329.7% | -287.2% | -117.0% | -243.3% | -558.1% | -453.8% | -465.5% | -445.6% |
| EPS (diluted) | -9.00 | -10.50 | -8.40 | -10.50 | -14.10 | -9.60 | -9.00 | -7.10 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-5.67 | $-7.10–$-4.47 | 2 |
| 2027 | $13M | $-3.87 | $-4.85–$-3.05 | 2 |
| 2028 | $26M | $-1.68 | $-2.10–$-1.26 | 2 |
| 2029 | $42M | $0.14 | $0.11–$0.18 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
IceCure Medical Ltd. Ordinary Shares
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
www.icecure-medical.com- Employees
- 66
- IPO / List date
- Nov 6, 2013
Held by traders on TradeandTell
No one on the platform currently holds ICCM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ICCM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-04 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded ICCM yet.
